Biocartis Group N.V. | Balance Sheet

Fiscal year is January-December. All values EUR Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
29,047.00
10,919.00
104,087.00
83,246.00
112,765.00
63,539
Total Accounts Receivable
7,924.00
18,108.00
7,564.00
5,911.00
10,387.00
13,861
Inventories
1,116.00
3,583.00
5,837.00
9,829.00
9,060.00
11,919
Total Current Assets
38,087.00
32,610.00
117,488.00
98,986.00
132,212.00
89,319
Net Property, Plant & Equipment
11,199.00
9,154.00
14,245.00
23,088.00
26,199.00
30,391
Total Investments and Advances
245.00
-
5,052.00
5,052.00
5,052.00
5,052
Long-Term Note Receivable
107.00
117.00
11.00
11.00
11.00
11
Intangible Assets
9,985.00
9,652.00
8,987.00
9,921.00
10,267.00
6,579
Other Assets
522.00
532.00
609.00
1,157.00
878.00
1,464
Total Assets
60,145.00
53,012.00
148,378.00
141,305.00
181,191.00
139,385
ST Debt & Current Portion LT Debt
3,373.00
5,057.00
8,152.00
3,698.00
4,029.00
Accounts Payable
5,847.00
4,265.00
13,927.00
6,293.00
5,555.00
Income Tax Payable
-
1,791.00
-
4.00
-
Other Current Liabilities
2,429.00
6,601.00
5,798.00
4,913.00
6,216.00
Total Current Liabilities
11,649.00
17,714.00
27,877.00
14,908.00
15,800.00
Long-Term Debt
12,822.00
8,528.00
2,662.00
27,709.00
31,359.00
Provision for Risks & Charges
267.00
-
-
47.00
16.00
Deferred Taxes
-
947.00
1,986.00
3,090.00
6,572.00
Other Liabilities
3,452.00
6,490.00
2,923.00
1,752.00
1,777.00
Total Liabilities
28,190.00
32,732.00
33,462.00
44,416.00
48,952.00
Common Equity (Total)
31,955.00
20,280.00
114,916.00
96,889.00
132,239.00
Total Shareholders' Equity
31,955.00
20,280.00
114,916.00
96,889.00
132,239.00
Total Equity
31,955.00
20,280.00
114,916.00
96,889.00
132,239.00
Liabilities & Shareholders' Equity
60,145.00
53,012.00
148,378.00
141,305.00
181,191.00

About Biocartis Group

View Profile
Address
Generaal de Wittelaan 11 B3
Mechelen VL 2800
Belgium
Employees -
Website http://www.biocartis.com
Updated 07/08/2019
Biocartis Group NV is a commercial stage molecular diagnostics company, which engaegs in the provision of diagnostic solutions. It operates through MDx Idylla™ platform, an automated sample-to-result, real-time polymerase chain reaction system that offers molecular information from virtually any biological sample. The company was founded by Renaud Philippe, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.